HanAll Biopharma and Daewoong Pharmaceutical Announced the R..
IM156, a new drug with original technology of HanAll Biopharma(CO-CEO Seung-kook Park and Jae-chun Yun), is to be Introduced at the American Society of Clinical Oncology(ASCO) held in Chicago for five days starting June 1.
IM156 is a new anticancer drug that is under phase 1 clinical trial
at ImmunoMet, a spun-off company, after completion of preclinical trial at
HanAll Biopharma, and it showed the treatment efficacy for △ glioblastoma △
gastric cancer △ lymphoma.
The new drug has a mechanism to prevent the growth of cancer by
inhibiting energy metabolism of tumors. Phase 1 clinical trial of the drug will
be completed by the end of this year and phase 2 clinical trial will begin next
year.
An official of ImmunoMet said, “IM156 is a leading drug candidate of
ImmunoMet, a company derived from HanAll Biopharma, and we expect that it will
give hope to patients suffering from intractable cancers as a medicine that can
treat cancer cells in new ways.” “ImmunoMet’s growth will also be with IM156,”
he added.
HanAll Biopharma owns about 11% of ImmunoMet’s shares as of the end
of last year. HanAll transferred the technology of IM156, an anticancer drug,
and singed a profit-sharing contract on the drug with ImmunoMet. Therefore,
they will share revenue made from the drug when the drug is commercialized or
licensed out.
Meanwhile, ASCO was established in 1964 as the world\'s largest
cancer-related event, and it is consisted of more than 40,000 members who are
physicians.